Akari Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Akari Therapeutics.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Akari Therapeutics GAAP EPS of $0.00

Sep 27

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Sep 20

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Jul 28

Akari Therapeutics GAAP EPS of $0.00

Jul 20

Patient completes course with Akari's stem cell transplant related complication treatment

Jul 07

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Dec 31

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Apr 28

Akari Therapeutics reports FY results

Apr 21

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Mar 15

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Dec 03

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Akari Therapeutics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:AKTX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	N/A	-20	-15	-15	N/A
6/30/2024	N/A	-20	-16	-16	N/A
3/31/2024	N/A	-17	-16	-16	N/A
12/31/2023	N/A	-10	-16	-16	N/A
9/30/2023	N/A	-10	-17	-17	N/A
6/30/2023	N/A	-10	-17	-17	N/A
3/31/2023	N/A	-12	-21	-21	N/A
12/31/2022	N/A	-18	-22	-22	N/A
9/30/2022	N/A	-20	-23	-23	N/A
6/30/2022	N/A	-18	-20	-20	N/A
3/31/2022	N/A	-17	-16	-16	N/A
12/31/2021	N/A	-17	-19	-19	N/A
9/30/2021	N/A	-18	-18	-18	N/A
6/30/2021	N/A	-16	-17	-17	N/A
3/31/2021	N/A	-19	-17	-17	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-18	-16	-16	N/A
6/30/2020	N/A	-21	-20	-20	N/A
3/31/2020	N/A	-18	-21	-21	N/A
12/31/2019	N/A	-17	-13	-13	N/A
9/30/2019	N/A	-13	-14	-14	N/A
6/30/2019	N/A	-14	-14	-14	N/A
3/31/2019	N/A	-18	-18	-18	N/A
12/31/2018	N/A	-20	-23	-23	N/A
9/30/2018	N/A	-25	-27	-27	N/A
6/30/2018	N/A	-32	N/A	-30	N/A
3/31/2018	N/A	-24	N/A	-27	N/A
12/31/2017	N/A	-35	N/A	-32	N/A
9/30/2017	N/A	-32	N/A	-30	N/A
6/30/2017	N/A	-22	N/A	-25	N/A
3/31/2017	N/A	-28	N/A	-26	N/A
12/31/2016	N/A	-18	N/A	-25	N/A
9/30/2016	N/A	-3	N/A	-25	N/A
6/30/2016	N/A	-52	N/A	-15	N/A
3/31/2016	N/A	-47	N/A	-10	N/A
12/31/2015	N/A	-45	N/A	-5	N/A
9/30/2015	N/A	-53	N/A	1	N/A
6/30/2015	N/A	-4	N/A	-4	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de AKTX es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de AKTX crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de AKTX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de AKTX crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de AKTX crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AKTX se prevé que sea elevada dentro de 3 años.

Akari Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$4.00

Recent updates

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc announced that it expects to receive $3.2 million in funding

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

Price target decreased to US$4.00

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics GAAP EPS of $0.00

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

New 90-day high: US$3.88

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to Treat Neuropathic Pain and Dermatological Disease

Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?

New 90-day high: US$2.05

Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares

New 90-day high: US$2.00

Akari Therapeutics, Plc Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Akari Therapeutics updates trial progress; returns to profitability

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

New 90-day low: US$1.50

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia